Abstract
Nineteen patients with different clinical subsets of cutaneous lupus erythematosus (LE) were treated with the aromatic retinoid etretinate. In 11 of them excellent or good treatment results were obtained within two to six weeks. Best response to etretinate therapy was seen in male patients with discoid lupus erythematosus. Etretinate should prove a valuable drug in LE therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Acta Dermato-Venereologica
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
